ArticleBMC cancer2025
Immunotherapy concurrently administered with chemoradiotherapy in limited-stage small-cell lung cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundFew advancements in treating limited-stage small-cell lung cancer (LS-SCLC) have been made in decades. We aim to explore the efficacy and safety of immune checkpoint inhibitors (ICIs) in combination with concurrent chemoradiotherapy (cCRT) for treating LS-SCLC.
methodsThis study recruited patients with LS-SCLC. cCRT consisted of etoposide and a platin with once daily (60 Gy/30 fractions) or twice daily radiotherapy (45 Gy/30 fractions). ICIs was started concurrently with cCRT and continued for up to 2 years. The primary endpoint was progression-free survival (PFS) and safety.
resultsA total of 29 patients were enrolled. All patients underwent at least one cycle of ICI during cCRT. With the median follow-up duration of 28.4 months, the median PFS was 13.1 months (95% CI: 10.7-15.6), and the 2-year PFS rate was 40%. The median OS was not reached with a 2-year OS rate of 69.8%. The objective response was achieved in 72.4% of patients. There were no grade 5 toxicities, but there was one grade 3 allergic reaction. Pneumonitis with a grade 3 rate was 10.3%. All 21 esophagitis events (72.4%) were grade 1 to 2. There were several grade 4 (10.3%) events (neutropenia) which were well managed.
conclusionICIs concurrent with cCRT for LS-SCLC exhibited promising clinical efficacy. The relatively high incidence of grade 3 pneumonitis suggests that the selection of cCRT combined with ICI requires careful consideration in clinical practice for some patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.